Neural cell adhesion molecule-180 expression as a prognostic criterion in colorectal carcinoma: feasible or not?

To evaluate the frequency of neural cell adhesion molecule (NCAM)-180 expression in fresh tumor tissue samples and to discuss the prognostic value of NCAM-180 in routine clinical practice. Twenty-six patients (16 men, 10 women) with colorectal cancer were included in the study. Fresh tumor tissue sa...

Full description

Saved in:
Bibliographic Details
Published in:World journal of gastroenterology : WJG 2007-11, Vol.13 (41), p.5476-5480
Main Authors: Tascilar, Oge, Cakmak, Güldeniz Karadeniz, Tekin, Ishak Ozel, Emre, Ali-Ugur, Ucan, Bulent Hamdi, Irkorucu, Oktay, Karakaya, Kemal, Gül, Mesut, Engin, Hüseyin Bülent, Comert, Mustafa
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Biomarkers, Tumor - analysis
Cell Differentiation
Colorectal Neoplasms - chemistry
Colorectal Neoplasms - diagnosis
Colorectal Neoplasms - mortality
Colorectal Neoplasms - pathology
Colorectal Neoplasms - therapy
Feasibility Studies
Female
Flow Cytometry - methods
Humans
Male
Middle Aged
Neoplasm Staging
Neural Cell Adhesion Molecules - analysis
Predictive Value of Tests
Prognosis
Rapid Communication
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the frequency of neural cell adhesion molecule (NCAM)-180 expression in fresh tumor tissue samples and to discuss the prognostic value of NCAM-180 in routine clinical practice. Twenty-six patients (16 men, 10 women) with colorectal cancer were included in the study. Fresh tumor tissue samples and macroscopically healthy proximal margins of each specimen were subjected to flow-cytometric analysis for NCAM-180 expression. Flow-cytometric analysis determined NCAM-180 expression in whole tissue samples of macroscopically healthy colorectal tissues. However, NCAM-180 expression was positive in only one case (3.84%) with well-differentiated Stage II disease who experienced no active disease at 30 mon follow-up. As a consequence of the limited number of cases in our series, it might not be possible to make a generalisation, nevertheless the routine use of NCAM-180 expression as a prognostic marker for colorectal carcinoma seems to be unfeasible and not cost-effective in clinical practice due to its very low incidence.
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v13.i41.5476